Tinidazole
Tindamax (tinidazole) is a small molecule pharmaceutical. Tinidazole was first approved as Tindamax on 2004-05-17. It is used to treat amebiasis, bacterial infections, bacterial vaginosis, giardiasis, and protozoan infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| digestive system diseases | D004066 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Tindamax (generic drugs available since 2012-04-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tinidazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TINDAMAX | Mission Pharmacal | N-021618 RX | 2004-05-17 | 2 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| amebiasis | EFO_0007144 | D000562 | A06 |
| bacterial infections | — | D001424 | A49 |
| bacterial vaginosis | EFO_0003932 | D016585 | — |
| giardiasis | DOID_10718 | D005873 | A07.1 |
| protozoan infections | — | D011528 | B50-B64 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD09: Lansoprazole, clarithromycin and tinidazole
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA11: Ciprofloxacin and tinidazole
— J01RA13: Norfloxacin and tinidazole
— J01X: Other antibacterials in atc
— J01XD: Imidazole derivatives, antibacterial for systemic use
— J01XD02: Tinidazole
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AB: Nitroimidazole derivatives, antiprotozoal agents against amoebiasis and other protozoal diseases
— P01AB02: Tinidazole
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tardive dyskinesia | D000071057 | G24.01 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
| Psychotic disorders | D011618 | F20.81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TINIDAZOLE |
| INN | tinidazole |
| Description | Tinidazole is 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. It has a role as an antiprotozoal drug, an antibacterial drug, an antiparasitic agent and an antiamoebic agent. |
| Classification | Small molecule |
| Drug class | antiprotozoal substances (metronidazole type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C |
Identifiers
| PDB | — |
| CAS-ID | 19387-91-8 |
| RxCUI | 10612 |
| ChEMBL ID | CHEMBL1220 |
| ChEBI ID | 63627 |
| PubChem CID | 5479 |
| DrugBank | DB00911 |
| UNII ID | 033KF7V46H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,570 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tindamax, Tindazole
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,986 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more